Envafolimab combined with chemotherapy in the treatment of combined small cell lung cancer: A case report

Table 1 Information on the treatment of combined small cell lung cancer patients, including their interventions and clinical outcomes, collected from the literature

Ref.	Year	Intervention	Clinical outcome
Li[15]	2022	Durvalumab 15 mg/kg, etoposide, and carboplatin (at 70% of the standard doses) every 3 wk	The patient responded well to treatment and survived for 19 mo at the time of publication
Dong et al[7]	2022	Camrelizumab 200 mg ig d1, albumin paclitaxel 400 mg ig d1, cisplatin 60mg ig d1-2/q3w	After 4 cycles of chemotherapy, lung lesions were significantly reduced
Niitsu et al[14]	2020	Alectinib	The patient has been receiving alectinib treatment for five months, without disease progression or remarkable adverse events
Wang et al[15]	2022	Nivolumab combined with radiotherapy	Clinical complete remission